Cambridge, MA - CluePoints, a leading provider of Centralized Statistical Monitoring (CSM) solutions for clinical trials, today introduced software to enable analyses of operational data using a risk-based monitoring approach at DIA 2015. The new software includes Key Risk Indicators (KRIs) that perfectly complement the statistical analysis of clinical data. This KRI+ approach allows sponsors and CROs to set their own subjective threshold levels, while also statistically examining data objectively to show how a single site's KRIs can be judged against results across all other sites. CluePoints will demonstrate its latest software offering on booth #1511 at the DIA 2015 51st Annual Meeting in Washington, DC.
CluePoints' award-winning SMART™ Engine lies at the heart of the solution and has been designed to offer independent and objective interrogation of clinical data, leaving no stone unturned in assessing data quality and integrity. The enhancement of the engine with the KRI+ approach provides users with the powers of statistical analysis alongside their own triggers for action across key operational variables. This means that more frequent operational analyses can be conducted, and, when coupled with exhaustive interrogation of all clinical data, the software ensures that sponsors and CROs are able to de-risk studies and improve data quality and integrity using an automated approach. Additionally, the new software will soon support an online, customizable version of the Transcelerate-recommended Risk-Assessment Categorization Tool (RACT), allowing the CluePoints monitoring platform to provide upfront study/site risk assessment.
"With our latest software release we wanted to enable our customers to incorporate objective statistical analysis, while also allowing users to assess key operational variables to provide the most meticulous interrogation of all clinical data", comments FranÒ«ois Torche, CEO, CluePoints. "This is our latest advancement in helping our customers move towards 0% SDV and 100% data quality oversight, enabling clinical workflows to be streamlined and resources to be more effectively managed by focusing attention on the sites and data that really matter."
At the DIA 2015 Annual Meeting CluePoints' data quality thought leaders will present two interactive sessions. Delegates can learn about 'Ensuring Data Quality and Detecting Potential Fraud' on Tuesday, June 16 at 8:00-9:30am (#209, Track 07A) and 'Integrating Central Statistical Monitoring in a Quality by Design Approach for Clinical Trials' on Wednesday, June 17 at 3:30-5:00pm (#391 Track 15).
For further information on CluePoints or to request a demo of the new software, please visit booth #1511 at the DIA 2015 Annual Meeting or www.CluePoints.com
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.